<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280421</url>
  </required_header>
  <id_info>
    <org_study_id>M522101-EU21</org_study_id>
    <nct_id>NCT02280421</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study: ASP2151 and Ciclosporin</brief_title>
  <official_title>A Single-centre, Open-label, Randomised, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Repeated Oral Doses of Ciclosporin on the Single-dose Pharmacokinetics of nASP2151 in Healthy Mean</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Europe Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Europe Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue
      transplantation may be prescribed ciclosporin to suppress their immune system to give the
      transplant an increased chance of not being rejected. A patient with a compromised immune
      system is more susceptible to infections such as herpes, which will require treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of ASP2151</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Peak Concentration (Tmax) of ASP2151</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of ASP2151</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life (t1/2) of ASP2151</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of ASP2151 From Plasma</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of ASP2151</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to 31 days after the Day 7 dose of ASP2151</time_frame>
    <description>Refer to the result of adverse event.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of ASP1955888-00</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Peak Concentration (Tmax) of AS195588-00</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC) of AS195588-00</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-Life (t1/2) of AS195588-00</measure>
    <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Ciclosporin</measure>
    <time_frame>Blood samples were taken at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 after dosing of ciclosporin on Days 6 and 7.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Peak Concentration (Tmax) of Ciclosporin</measure>
    <time_frame>Blood samples were taken at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 after dosing of ciclosporin on Days 6 and 7.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC) of Ciclosporin</measure>
    <time_frame>Blood samples were taken at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 after dosing of ciclosporin on Days 6 and 7.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ASP2151 400mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ASP2151 400mg + 100mg ciclosporin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151 1200mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ASP2151 1200mg + 100mg ciclosporin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151 400mg + 100mg ciclosporin</intervention_name>
    <arm_group_label>ASP2151 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151 1200mg + 100mg ciclosporin</intervention_name>
    <arm_group_label>ASP2151 1200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (Quetelet index) in the range 18.0-30.9 kg/m2.

          -  Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the investigator and
             to participate in, and comply with the requirements of, the entire trial.

          -  Willingness to give written consent to participate after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             investigator or his delegate.

          -  Willingness to give written consent to have data entered into The Overvolunteering
             Prevention System (TOPS).

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at
             the pre-trial screening assessment that could interfere with the objectives of the
             trial or the safety of the volunteer.

          -  Any of the following liver function tests higher than 1.5 times the ULN at the
             screening visit: aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             alkaline phosphatase (ALP), bilirubin, gamma glutamyl transpeptidase (gamma-GT).

          -  Platelet counts outside normal limits.

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate the volunteer's participation in the trial or make it unnecessarily
             hazardous.

          -  Clinically significant impaired endocrine, thyroid, hepatic, respiratory or renal
             function, diabetes mellitus, coronary heart disease, or history of any psychotic
             mental illness.

          -  Receipt of a live vaccine in the 3 months before the first dose of study medication,
             or planned immunisation with a live vaccine during the study.

          -  Evidence of any significant bacterial, viral, fungal or parasitic infection during the
             4 weeks before dosing (minor fungal nail infections will not be regarded as
             significant); minor infection (eg common cold) not requiring anti-infective treatment
             during the 2 weeks before dosing.

          -  History of bleeding diathesis.

          -  Surgery (eg stomach bypass) or medical condition that might affect absorption of
             medicines.

          -  Presence or history of severe adverse reaction to any drug, history of multiple drug
             allergies (multiple defined as &gt;3), or sensitivity to trial medication.

          -  Use, during the 28 days before the first dose of trial medication, of any prescription
             medicine, or any other medicine or herbal remedy (such as St John's wort) known to
             interfere with the CYP3A4 metabolic pathway (unless judged as not clinical significant
             by the investigator and sponsor). See Appendix 1 for common CYP3A4
             interactors/substrates.

          -  Use, during the 7 days before the first dose of trial medication, of any
             over-the-counter medicine, with the exception of paracetamol (acetaminophen).

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months.

          -  Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood
             donor.

          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of
             alcohol weekly or more than 5 cigarettes daily.

          -  Evidence of drug abuse on urine testing.

          -  Positive test for hepatitis B antigen (HBsAg); or positive test for hepatitis B core
             antibody (HBcAb).

          -  Positive test for hepatitis C, HIV1, HIV2, or active and latent tuberculosis.

          -  Blood pressure and heart rate in seated position at the screening examination outside
             the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min.

          -  Possibility that the volunteer will not cooperate with the requirements of the
             protocol.

          -  Objection by General Practitioner (GP) to volunteer entering trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <results_first_submitted>July 9, 2018</results_first_submitted>
  <results_first_submitted_qc>January 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2019</results_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>Herpes</keyword>
  <keyword>volunteers</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at one investigative site in United Kingdom from 06-October 2014 to 10-February 2015
Each participant was randomised to 2 groups. One group was received ASP 400mg in first intervention and 1200mg in other group. There was a washout of at least 2 weeks between the interventions.</recruitment_details>
      <pre_assignment_details>Participants received a single dose of 400mg or 1200mg ASP2151 on Days 1 and 7, 100 mg ciclosporin twice daily on Days 3â€“9, and once in the morning of Day 10. Two participants were withdrawn during the washout period, in the second intervention, another participants were replaced.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ASP2151 400mg</title>
          <description>&quot;ASP2151 400mg followed by ASP2151 400mg + 100mg ciclosporin&quot; first, then &quot;ASP and 1200mg mg followed by ASP2151 1200mg + 100mg ciclosporin&quot;</description>
        </group>
        <group group_id="P2">
          <title>ASP2151 1200mg</title>
          <description>&quot;ASP2151 1200mg followed by ASP2151 1200mg + 100mg ciclosporin&quot; first, then &quot;ASP and 400mg mg followed by ASP2151 400mg + 100mg ciclosporin&quot;</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention(2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention(2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ASP2151 400mg</title>
          <description>&quot;ASP2151 400mg followed by ASP2151 400mg + 100mg ciclosporin&quot; first, then &quot;ASP and 1200mg mg followed by ASP2151 1200mg + 100mg ciclosporin&quot;</description>
        </group>
        <group group_id="B2">
          <title>ASP2151 1200mg</title>
          <description>&quot;ASP2151 1200mg followed by ASP2151 1200mg + 100mg ciclosporin&quot; first, then &quot;ASP and 400mg mg followed by ASP2151 400mg + 100mg ciclosporin&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="7.4"/>
                    <measurement group_id="B2" value="31.8" spread="7.1"/>
                    <measurement group_id="B3" value="32.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of ASP2151</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of ASP2151</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1818.0" spread="26.1"/>
                    <measurement group_id="O2" value="1202.3" spread="31.5"/>
                    <measurement group_id="O3" value="3573.1" spread="26.1"/>
                    <measurement group_id="O4" value="2452.1" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Peak Concentration (Tmax) of ASP2151</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of ASP2151</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.50" upper_limit="4.02"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of ASP2151</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of ASP2151</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23307.4" spread="27.1"/>
                    <measurement group_id="O2" value="19013.5" spread="31.4"/>
                    <measurement group_id="O3" value="48051.2" spread="25.0"/>
                    <measurement group_id="O4" value="37940.8" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-Life (t1/2) of ASP2151</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life (t1/2) of ASP2151</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.755" spread="12.1"/>
                    <measurement group_id="O2" value="8.593" spread="16.4"/>
                    <measurement group_id="O3" value="7.457" spread="13.2"/>
                    <measurement group_id="O4" value="8.326" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) of ASP2151 From Plasma</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) of ASP2151 From Plasma</title>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.745" spread="4.6288"/>
                    <measurement group_id="O2" value="21.917" spread="5.9182"/>
                    <measurement group_id="O3" value="25.695" spread="6.3004"/>
                    <measurement group_id="O4" value="32.699" spread="9.3284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/F) of ASP2151</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) of ASP2151</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.9" spread="45.72"/>
                    <measurement group_id="O2" value="269.6" spread="69.57"/>
                    <measurement group_id="O3" value="276.5" spread="69.55"/>
                    <measurement group_id="O4" value="395.3" spread="118.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Refer to the result of adverse event.</description>
        <time_frame>Up to 31 days after the Day 7 dose of ASP2151</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400 mg ASP Treatment</title>
            <description>400 mg ASP Treatment</description>
          </group>
          <group group_id="O2">
            <title>1200 mg ASP Treatment</title>
            <description>1200 mg ASP Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Refer to the result of adverse event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax) of ASP1955888-00</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of ASP1955888-00</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.0" spread="35.2"/>
                    <measurement group_id="O2" value="132.6" spread="28.1"/>
                    <measurement group_id="O3" value="387.3" spread="38.1"/>
                    <measurement group_id="O4" value="307.2" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Peak Concentration (Tmax) of AS195588-00</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of AS195588-00</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.00" upper_limit="8.08"/>
                    <measurement group_id="O3" value="3.53" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.00" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve (AUC) of AS195588-00</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of AS195588-00</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2614.4" spread="27.4"/>
                    <measurement group_id="O2" value="2441.3" spread="20.2"/>
                    <measurement group_id="O3" value="6147.4" spread="29.7"/>
                    <measurement group_id="O4" value="5584.5" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Half-Life (t1/2) of AS195588-00</title>
        <time_frame>prior to initial dose on Day 1 and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ASP2151 dosing on Day 1 and Day 7, and also 72 h after ASP2151 dosing on Day 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151 400mg Alone</title>
            <description>ASP2151(400mg) alone</description>
          </group>
          <group group_id="O2">
            <title>ASP2151 400mg With Ciclosporin</title>
            <description>ASP2151 400mg + 100mg ciclosporin
ASP2151 400mg + 100mg ciclosporin</description>
          </group>
          <group group_id="O3">
            <title>ASP2151 1200mg Alone</title>
            <description>ASP2151(1200mg) alone</description>
          </group>
          <group group_id="O4">
            <title>ASP2151 1200mg With Ciclosporin</title>
            <description>ASP2151 1200mg + 100mg ciclosporin
ASP2151 1200mg + 100mg ciclosporin</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life (t1/2) of AS195588-00</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="15.3"/>
                    <measurement group_id="O2" value="9.62" spread="18.4"/>
                    <measurement group_id="O3" value="8.25" spread="14.3"/>
                    <measurement group_id="O4" value="9.02" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax) of Ciclosporin</title>
        <time_frame>Blood samples were taken at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 after dosing of ciclosporin on Days 6 and 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclosporin After ASP2151(400mg)</title>
            <description>Ciclosporin after ASP2151(400mg)</description>
          </group>
          <group group_id="O2">
            <title>Ciclosporin With ASP2151(400mg)</title>
            <description>Ciclosporin with ASP2151(400mg)</description>
          </group>
          <group group_id="O3">
            <title>Ciclosporin After ASP2151(1200mg)</title>
            <description>Ciclosporin after ASP2151(1200mg)</description>
          </group>
          <group group_id="O4">
            <title>Ciclosporin With ASP2151(1200mg)</title>
            <description>Ciclosporin with ASP2151(1200mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of Ciclosporin</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491.0" spread="18.6"/>
                    <measurement group_id="O2" value="482.3" spread="18.3"/>
                    <measurement group_id="O3" value="467.0" spread="23.7"/>
                    <measurement group_id="O4" value="440.0" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Peak Concentration (Tmax) of Ciclosporin</title>
        <time_frame>Blood samples were taken at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 after dosing of ciclosporin on Days 6 and 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclosporin After ASP2151(400mg)</title>
            <description>Ciclosporin after ASP2151(400mg)</description>
          </group>
          <group group_id="O2">
            <title>Ciclosporin With ASP2151(400mg)</title>
            <description>Ciclosporin with ASP2151(400mg)</description>
          </group>
          <group group_id="O3">
            <title>Ciclosporin After ASP2151(1200mg)</title>
            <description>Ciclosporin after ASP2151(1200mg)</description>
          </group>
          <group group_id="O4">
            <title>Ciclosporin With ASP2151(1200mg)</title>
            <description>Ciclosporin with ASP2151(1200mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of Ciclosporin</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.92" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.98" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve (AUC) of Ciclosporin</title>
        <time_frame>Blood samples were taken at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 after dosing of ciclosporin on Days 6 and 7.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclosporin After ASP2151(400mg)</title>
            <description>Ciclosporin after ASP2151(400mg)</description>
          </group>
          <group group_id="O2">
            <title>Ciclosporin With ASP2151(400mg)</title>
            <description>Ciclosporin with ASP2151(400mg)</description>
          </group>
          <group group_id="O3">
            <title>Ciclosporin After ASP2151(1200mg)</title>
            <description>Ciclosporin after ASP2151(1200mg)</description>
          </group>
          <group group_id="O4">
            <title>Ciclosporin With ASP2151(1200mg)</title>
            <description>Ciclosporin with ASP2151(1200mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Ciclosporin</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1944.3" spread="19.7"/>
                    <measurement group_id="O2" value="2011.0" spread="22.1"/>
                    <measurement group_id="O3" value="1894.2" spread="22.9"/>
                    <measurement group_id="O4" value="1888.2" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ASP2151(400mg) Alone</title>
          <description>Participants who administered ASP2151 alone during the treatment session 1(ASP2151 400mg)</description>
        </group>
        <group group_id="E2">
          <title>Ciclosporin After ASP2151(400mg)</title>
          <description>Participants who administered ciclosporin alone during the treatment session 1(ASP2151 400mg)</description>
        </group>
        <group group_id="E3">
          <title>Ciclosporin With ASP2151(400mg)</title>
          <description>Participants who coadministered ciclosporin and ASP2151during the treatment session 1(ASP2151 400mg)</description>
        </group>
        <group group_id="E4">
          <title>ASP2151(1200mg) Alone</title>
          <description>Participants who administered ASP2151 alone during the treatment session 1(ASP2151 1200mg)</description>
        </group>
        <group group_id="E5">
          <title>Ciclosporin After ASP2151(1200mg)</title>
          <description>Participants who administered ciclosporin alone during the treatment session 1(ASP2151 1200mg)</description>
        </group>
        <group group_id="E6">
          <title>Ciclosporin With ASP2151(1200mg)</title>
          <description>Participants who coadministered ciclosporin and ASP2151during the treatment session 1(ASP2151 1200mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA/</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maruho Co.,Ltd. Kyoto R&amp;D Center</name_or_title>
      <organization>Clinical Development Dept.</organization>
      <phone>+81-75-325-3255</phone>
      <email>ctinfo@mii.maruho.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

